AstraZeneca Says Experimental Stomach Cancer Drug Doubled Survival
Photo: TokenPost
A late-stage study found twice the survival time with AstraZeneca’s experimental stomach cancer drug sonesitatug vedotin, the company said. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.
Source: TokenPost
